CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Realm Therapeutics plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Realm Therapeutics plc
78 Cannon Street
Phone: (484) 321-2700p:484 321-2700 London, PA  EC4N 6AF  United Kingdom Fax: (484) 321-2725f:484 321-2725
This company was Merged or Acquired on 7/31/2019.
This company ceased filing statements with the SEC on 8/1/2019.
This is a Subsidiary, click here for the Parent Company
Business Summary
Realm Therapeutics plc, formerly PuriCore plc, is a biopharmaceutical company. The Company is focused on leveraging its immunomodulatory technology to protect and improve the health of adults and children. The Company has initiated drug development programs based on its hypochlorous acid technology. The Company is engaged in the development of small molecule therapies with potential application for the treatment of diseases in a number of therapeutic areas, and an initial focus in dermatology and ophthalmology. The Company has developed proprietary formulations of its technology, with anti-inflammatory and immunomodulatory benefits. Its pipeline of products include PR013 and PR022, which are in Phase I. PR013 is indicated for allergic conjunctivitis and PR022 is indicated for atopic dermatitis. Realm Therapeutics, Inc. is a subsidiary of the Company.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201812/31/2018YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman Charles A.Spicer 51 6/23/2014 6/1/2013
Chief Executive Officer, Executive Director John A.Martin 49 6/18/2015 5/19/2015
Chief Financial Officer, Finance Director, Chief Operating Officer, Executive Director, Company Sec MarellaThorell 50 10/14/2014 10/7/2011
Non-Executive Director of the Board BalkrishanGill 51 3/1/2016 3/1/2016
Non-Executive Director SanfordZweifach 12/1/2017 12/1/2017

Business Names
Business Name
3HD
Labcaire Systems
PURI
6 additional Business Names available in full report.

General Information
Number of Employees: 12 (As of 12/31/2018)
Outstanding Shares: 116,561,917 (As of 12/31/2018)
Stock Exchange: SEA
Federal Tax Id: 133933588
Fax Number: (484) 321-2725


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023